CY1119998T1 - Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου - Google Patents

Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου

Info

Publication number
CY1119998T1
CY1119998T1 CY20171101268T CY171101268T CY1119998T1 CY 1119998 T1 CY1119998 T1 CY 1119998T1 CY 20171101268 T CY20171101268 T CY 20171101268T CY 171101268 T CY171101268 T CY 171101268T CY 1119998 T1 CY1119998 T1 CY 1119998T1
Authority
CY
Cyprus
Prior art keywords
immune
treatment
imaging agent
drug consumption
antibody
Prior art date
Application number
CY20171101268T
Other languages
English (en)
Inventor
Jochen Kruip
Sanjiv S. Gambhir
Susanta K. Sarkar
Mathias Gebauer
Christian Lange
Ingo Focken
Richard Kimura
Arutselvan Natarajan
Ohad Ilovich
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14705455.5A external-priority patent/EP2953975B1/en
Application filed by Sanofi filed Critical Sanofi
Publication of CY1119998T1 publication Critical patent/CY1119998T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση σχετίζεται με μία συνοδό διαγνωστική προσδένουσα πρωτεΐνη που ομοιάζει με αντίσωμα με βάση το εξανθρωπισμένο μονοκλωνικό αντίσωμα, DS6, που πρόκειται να χρησιμοποιηθεί ως διαγνωστικό εργαλείο για την in vivo ανίχνευση και ποσοτικοποίηση του ογκοσχετιζόμενου MUC1 -sialoglycotope, CA6.
CY20171101268T 2013-02-05 2017-12-05 Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου CY1119998T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361761188P 2013-02-05 2013-02-05
EP14305081 2014-01-21
EP14705455.5A EP2953975B1 (en) 2013-02-05 2014-02-05 Immuno imaging agent for use with antibody-drug conjugate therapy
PCT/US2014/014903 WO2014124026A1 (en) 2013-02-05 2014-02-05 Immuno imaging agent for use with antibody-drug conjugate therapy

Publications (1)

Publication Number Publication Date
CY1119998T1 true CY1119998T1 (el) 2018-12-12

Family

ID=50138009

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101268T CY1119998T1 (el) 2013-02-05 2017-12-05 Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου

Country Status (4)

Country Link
CY (1) CY1119998T1 (el)
HR (1) HRP20171880T1 (el)
IL (1) IL240370A0 (el)
ZA (1) ZA201505491B (el)

Also Published As

Publication number Publication date
ZA201505491B (en) 2016-07-27
HRP20171880T1 (hr) 2018-01-12
IL240370A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201892386A1 (ru) Химерные нейротоксины
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
CL2016001460A1 (es) Anticuerpo pdi-1, fragmento unificador antígeno de la misma y aplicación médica de la misma
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
DK3026062T3 (da) Anti-pd-1-antistof og anvendelse deraf
UY35478A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA IL-1ß y/o IL-17
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR302013004419S1 (pt) Configuração aplicada em instrumento médico
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112016004003A2 (pt) Composto de tetrazolinona e uso do mesmo
DK3795072T3 (da) Intermitterende måling af partialtrykket af en analyt i hudvævet
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
DK3057979T3 (da) Proteiner med diagnostiske og terapeutiske anvendelser
ES2540255A1 (es) Método de aislamiento de cuerpos apoptóticos
DK3155304T3 (da) Rørledning med kompositholdestrimmel
TR201902547T4 (tr) Oksi̇dati̇f stresli̇ hastalarda parati̇roi̇d hormonunun ölçüm araçlari ve yöntemleri̇